Telemedicine allows you to consult with a doctor remotely through online questionnaires without the need for in-person visits
common brand names include Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide, a dual GIP/GLP-1 drug), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), Byetta and Bydureon (exenatide), Adlyxin (lixisenatide), and Rybelsus (oral semaglutide), with generic options currently including liraglutide and exenatide in some markets
R.MohammedS
IV therapy is also convenient with Mobile IV Nurses
Clinical Trial Insights In SURMOUNT-1 and SURPASS trials, Mounjaro showed: Up to 22.5% body weight reduction in non-diabetic obese patients Greater HbA1c reductions vs Ozempic and insulin in diabetics Reference : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reference : mounjaro.lilly.com/hcp/a1c-weight FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)
Fiber Complexes : Aid digestion and support GLP-1 response in the gut